A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs. R-ICE plus placebo in patients with DLBCL. The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40.
Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin
DRUG: SGN-40|DRUG: placebo|DRUG: rituximab|DRUG: etoposide|DRUG: carboplatin|DRUG: ifosfamide
Complete response as assessed by CT and PET scans and revised response criteria for malignant lymphoma., 9 weeks
Adverse events, laboratory values, and anti-drug antibody immune responses., 9 weeks|Partial response, failure free survival, overall survival, and response for one and two years following treatment., Every 3 months for 2 years
This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs. R-ICE plus placebo in patients with DLBCL. The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40.